title: Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study.
abstract: BACKGROUND
  Amisulpride is a second-generation antipsychotic which has been proved to be effective in the control of both positive and negative symptoms of schizophrenia. In this study we aimed to determine metabolic, endocrinologic and cardiac effects of amisulpride commonly used in our clinical practice.
  
  
  METHODS
  A total of 18 patients (11 males, 7 females) diagnosed with schizophrenia received amisulpride at the dosage of 800 mg/day and were followed up for 24 weeks. Positive and negative psychotic symptoms, extrapyramidal and sexual side effects, metabolic, endocrinologic and cardiac parameters were evaluated at regular intervals.
  
  
  RESULTS
  Significant improvement in both positive and negative symptoms was observed in patients starting from the second week of treatment. Prolactin levels increased significantly both in men and women starting from the measurement on day 4. Prolactin elevation was significantly higher in women than in men. Increase in total cholesterol level became significant at week 24. No other significant difference was observed between weeks 1 and 24 regarding the other parameters.
  
  
  CONCLUSIONS
  The clinical data from the present study supports the fact that amisulpride is an effective and safe antipsychotic drug, but elevates prolactin levels in both sexes.
authors: Zeynep
authors: Z
authors: Kotan
authors: Berrin
authors: B
authors: Ertepe
authors: Cengiz
authors: C
authors: Akkaya
authors: Emre
authors: E
authors: Sarandol
authors: Güven
authors: G
authors: Ozkaya
authors: Selçuk
authors: S
authors: Kirli
keywords: QT interval; amisulpride; efficacy; hormones; hyperprolactinemia; metabolic control; side effects
references: Neuro Endocrinol Lett. 2007 Dec;28(6):881-8
references: 18063941
references: Int Clin Psychopharmacol. 2004 Mar;19(2):63-9
references: 15076013
references: Med Sci Law. 2008 Apr;48(2):173-7
references: 18533580
references: Int J Clin Pract. 2007 Aug;61(8):1356-70
references: 17627711
references: Expert Opin Investig Drugs. 2004 Apr;13(4):315-29
references: 15102583
references: J Psychopharmacol. 2009 Aug;23(6):723-6
references: 18562408
references: Acta Psychiatr Scand. 2007 Apr;115(4):268-76
references: 17355517
references: Clin Exp Pharmacol Physiol. 1992 Sep;19(9):603-6
references: 1356671
references: Biol Psychiatry. 2005 Jun 15;57(12):1543-9
references: 15953491
references: Am J Psychiatry. 2002 Feb;159(2):180-90
references: 11823257
references: Pharmacopsychiatry. 2009 Jan;42(1):29-34
references: 19153944
references: Arch Gen Psychiatry. 2003 Dec;60(12):1228-35
references: 14662555
references: J Clin Psychopharmacol. 2001 Feb;21(1):8-13
references: 11199953
references: Biol Psychiatry. 1999 Jan 1;45(1):89-97
references: 9894580
references: J Pharmacol Exp Ther. 1997 Jan;280(1):83-97
references: 8996185
references: Lancet. 2009 Jan 3;373(9657):31-41
references: 19058842
references: Curr Med Res Opin. 2004;20(2):189-97
references: 15006013
references: Pharmacol Rev. 1985 Sep;37(3):249-332
references: 2869509
references: Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):92-6
references: 16938372
references: Prim Care Companion J Clin Psychiatry. 2003 Feb;5(1):6-14
references: 15156241
references: J Psychiatr Res. 1994 Sep-Oct;28(5):461-73
references: 7897617
references: J Psychopharmacol. 2007 Jun;21(4):400-4
references: 17050656
references: Neuro Endocrinol Lett. 2004 Dec;25(6):419-22
references: 15665803
references: Drug Saf. 2000 Mar;22(3):195-214
references: 10738844
references: Eur Psychiatry. 2003 Aug;18(5):209-19
references: 12927321
references: Int Clin Psychopharmacol. 2007 May;22(3):145-52
references: 17414740
references: Acta Psychiatr Scand Suppl. 1970;212:11-9
references: 4917967
references: CNS Drugs. 2001;15(7):537-51
references: 11510624
references: CMAJ. 2003 Sep 16;169(6):575-81
references: 12975226
references: Hosp Community Psychiatry. 1984 May;35(5):486-91
references: 6144626
references: J Clin Psychiatry. 2008 Apr;69(4):514-9
references: 18370570
references: Int Clin Psychopharmacol. 1997 May;12 Suppl 2:S29-36
references: 9218165
references: J Reprod Med. 1999 Dec;44(12 Suppl):1075-84
references: 10649814
references: J Psychopharmacol. 2008 Mar;22(2 Suppl):98-103
references: 18477626
references: Am J Psychiatry. 1999 Nov;156(11):1686-96
references: 10553730
references: Am J Psychiatry. 2003 Aug;160(8):1413-20
references: 12900302
references: CNS Drugs. 2005;19 Suppl 1:1-93
references: 15998156
references: Fortschr Neurol Psychiatr. 1982 Aug;50(8):267-73
references: 6127297
references: Psychopharmacology (Berl). 2004 Apr;173(1-2):112-5
references: 14647963
references: Neuropsychiatr Dis Treat. 2009;5:267-77
references: 19557121
references: Acta Psychiatr Scand Suppl. 2000;400:17-22
references: 10823307
references: J Int Med Res. 2001 Nov-Dec;29(6):451-66
references: 11803729
references: Eur Psychiatry. 2000 Aug;15(5):321-9
references: 11032464
references: J Clin Endocrinol Metab. 1996 Feb;81(2):586-90
references: 8636272
references: Clin Chem. 2001 Feb;47(2):346-8
references: 11159789
references: Br J Clin Pharmacol. 2001 Apr;51(4):317-24
references: 11318766
references: J Clin Psychiatry. 2006 Sep;67(9):1391-6
references: 17017825
references: Int Clin Psychopharmacol. 2006 Mar;21 Suppl 2:S11-5
references: 16601508
references: Acta Psychiatr Scand Suppl. 2000;400:23-7
references: 10823308
references: Neuropsychopharmacology. 2002 Dec;27(6):1071-81
references: 12464464
references: J Clin Psychopharmacol. 2010 Aug;30(4):391-5
references: 20531221
references: J Psychopharmacol. 2007 Sep;21(7):768-73
references: 17606473
references: Acta Psychiatr Scand. 2000 Jun;101(6):416-32
references: 10868465
references: J Psychopharmacol. 2008 Mar;22(2 Suppl):46-55
references: 18477620